OptiBiotix Health PLC SlimBiome® commercial & product development update (8284V)
November 08 2017 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 8284V
OptiBiotix Health PLC
08 November 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
SlimBiome(R) commercial and product development update
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care provides the following product development and
commercial update on its SlimBiome(R) product platform.
SlimBiome(R) Product and Application Development
Further to the manufacturing and supply agreement with Knighton
Foods announced on 1 November 2017, OptiBiotix is launching a new
improved version of its SlimBiome(R) product platform. The product
development has been achieved using Knighton's specialised powder
technology which makes SlimBiome(R) easier to dissolve, greatly
enhancing ease of use, flavour and mouthfeel. This will provide a
range of new product and application opportunities with partners in
the bakery (e.g. in store bakeries), snacking, food service (e.g.
coffee shops) and beverage categories and meet growing consumer
demand for 'on the go' products.
SlimBiome(R) Product Range Extension
The new improved SlimBiome(R) will be sold as an ingredient in
white label format, and in OptiBiotix's own brand GoFigure(R) range
of shakes and bars. New flavours and additions to the SlimBiome(R)
and GoFigure(R) product range will be introduced in early 2018
including morning muesli pots, healthy bites and coffee and tea
blends as part of a healthy lifestyle brand. This creates the
opportunity for multiple revenue streams from sales of ingredients
to food manufacturers, white label products to large retailers, and
branded products in multiple presentations to meet the needs of a
diverse range of national and international markets. This is all
part of a series of ongoing developments with a number of
international partners and large retailers to extend SlimBiome's(R)
application into a broader range of 'Health & Wellbeing' food
and beverage products.
SlimBiome(R) Territory Expansion
Further product development is ongoing with a number of
international partners to include SlimBiome(R) in territory
specific applications including bakery products (e.g. cookies,
tortillas), breakfast cereals (puffs and flakes), food toppings
(e.g. salad, breakfast) as well as developing country flavour
specific options for healthy snacks, yoghurts and cereal bars.
These include Tata with specially formulated and flavoured products
ranges for the Asian markets, and a number of US partners looking
to improve the health and nutritional status of existing snacking,
bakery and cereal products.
Stephen O'Hara, CEO of OptiBiotix, commented: "This announcement
updates investors on the significant progress we have made with
partners developing new application and product opportunities to
extend the use of SlimBiome(R) across a wider range of products
opportunities and territories. We anticipate SlimBiome(R) being the
first in a family of products to include: ImmunBiome, WellBiome,
OptiBiome(R) and CardioBiome(R), developed using our advanced
microbiome modulating technology platforms, to meet industry and
consumer need for scientifically proven products to improve health
and wellbeing. As the promise of the microbiome materialises into a
wider the range of applications and products and we extend into
overseas territories the scale of the opportunity enlarges allowing
us to fully exploit the revenue generating potential of our
products."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap Broker Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits.
This information is provided by RNS
The company news service from the London Stock Exchange
END
UPDGMMGMKNNGNZM
(END) Dow Jones Newswires
November 08, 2017 02:00 ET (07:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024